Protocol Ledger

NCT04468061 · Phase II · RECRUITING

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Interventional Phase II clinical trial protocol NCT04468061 sponsored by Dana-Farber Cancer Institute in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-07-20 Enrollment: 110 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04468061
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)110 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04468061
Protocol FieldVerified Registry Value
NCT IdentifierNCT04468061
Consolidated Lead SponsorDana-Farber Cancer Institute
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment110 participants (ESTIMATED)
Registered Start Date2020-07-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04468061
Hospital Research SiteLocationSite Profile
University of Chicago MedicineChicago, ILOpen Hospital Dossier ->
Dana-Farber Cancer InstituteBoston, MAOpen Hospital Dossier ->
Ohio State University Comprehensive Cancer CenterColumbus, OHOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Dana-Farber Cancer Institute across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI